Non-alcoholic fatty liver disease as an emerging risk factor and potential intervention target for atherosclerotic cardiovascular diseases

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an underappreciated independent risk factor for atherosclerotic cardiovascular diseases (ASCVDs). In recent years, the risk of ASCVD has increased along with the prevalence of NAFLD. ASCVD events are highly prevalent and are the main contributor to death in patients with NAFLD. The association between NAFLD and ASCVD has been validated in numerous observational, cohort, and genetic studies. Most of these studies agree that NAFLD significantly increases the risk of developing atherosclerosis and ASCVD. Additionally, the underlying pro-atherosclerotic mechanisms of NAFLD have been gradually revealed, both disorders share several common pathophysiologic mechanisms including insulin resistance, while systemic inflammation and dyslipidemia driven by NAFLD directly promote atherosclerosis. Recently, NAFLD, as an emerging risk enhancer for ASCVD, has attracted attention as a potential treatment target for ASCVD. This brief review aims to illustrate the potential mechanistic insights, present recent clinically relevant investigations, and further explore the emerging therapies such as novel anti-diabetic and lipid-lowering agents that could improve NAFLD and reduce ASCVD risk.